Glyxambi Is the First SGLT2/DPP-4 Inhibitor Oral Combo for Type 2 Diabetes

You'll see Glyxambi (glik-SAM-bee), a new combo for type 2 diabetes.

It contains the SGLT2 inhibitor empagliflozin (Jardiance)...with the DPP-4 inhibitor linagliptin (Trajenta).

Glyxambi will be promoted for patients who aren't at their glycemic goal with metformin plus either linagliptin or empagliflozin.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote